CIM
VRTX icon

CIM Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

CIM Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,374
Closed -$359K – 260
2022
Q1 		$359K Sell
1,374
-6,570
-83% -$1.56M 0.12% 158
2021
Q4 		$1.75M Buy
7,944
+1,485
+23% +$289K 0.52% 24
2021
Q3 		$1.17M Buy
6,459
+2,075
+47% +$405K 0.37% 44
2021
Q2 		$884K Buy
4,384
+2,671
+156% +$559K 0.27% 76
2021
Q1 		$368K Sell
1,713
-59
-3% -$13K 0.12% 175
2020
Q4 		$419K Buy
+1,772
New +$407K 0.14% 157
2020
Q1 		– Sell
-3,025
Closed -$662K – 239
2019
Q4 		$662K Hold
3,025
– – 0.26% 95
2019
Q3 		$512K Sell
3,025
-311
-9% -$55K 0.19% 123
2019
Q2 		$612K Buy
3,336
+126
+4% +$22K 0.22% 97
2019
Q1 		$590K Buy
3,210
+1,625
+103% +$300K 0.23% 96
2018
Q4 		$263K Sell
1,585
-65
-4% -$11.3K 0.11% 237
2018
Q3 		$318K Sell
1,650
-1,645
-50% -$293K 0.11% 261
2018
Q2 		$560K Sell
3,295
-94
-3% -$14.6K 0.19% 137
2018
Q1 		$552K Sell
3,389
-84
-2% -$13.7K 0.19% 143
2017
Q4 		$520K Sell
3,473
-53
-2% -$7.85K 0.18% 158
2017
Q3 		$536K Sell
3,526
-202
-5% -$30.4K 0.19% 147
2017
Q2 		$480K Sell
3,728
-59
-2% -$7.1K 0.17% 176
2017
Q1 		$414K Sell
3,787
-356
-9% -$31.3K 0.14% 192
2016
Q4 		$305K Buy
4,143
+48
+1% +$3.91K 0.11% 255
2016
Q3 		$357K Sell
4,095
-320
-7% -$30.2K 0.14% 205
2016
Q2 		$380K Sell
4,415
-190
-4% -$16.4K 0.16% 172
2016
Q1 		$366K Sell
4,605
-550
-11% -$49.7K 0.16% 166
2015
Q4 		$649K Sell
5,155
-5,165
-50% -$624K 0.3% 119
2015
Q3 		$1.07M Hold
10,320
– – 0.52% 54
2015
Q2 		$1.27M Sell
10,320
-48
-0.5% -$6.05K 0.56% 47
2015
Q1 		$1.22M Hold
10,368
– – 0.53% 51
2014
Q4 		$1.23M Buy
+10,368
New +$1.17M 0.56% 53

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CIM Investment Management's VRTX Position: Q2 2022 in Review

CIM Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 1,374 shares — an estimated $359K sold.

CIM Investment Management first reported a position in VRTX in Q4 2014 and held it in 27 quarters. The position peaked at $1.75M in Q4 2021. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • CIM Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • CIM Investment Management sold 1,374 Vertex Pharmaceuticals shares in Q2 2022, an estimated $359K.
  • CIM Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 27 quarters.
  • CIM Investment Management's Vertex Pharmaceuticals position peaked at $1.75M in Q4 2021.
  • 1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on CIM Investment Management's 13F filing for Q2 2022, filed 2 Sep 2022.